CASI Pharmaceuticals, Inc. (CASI) Institutional Ownership

Ownership Summary

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) currently has 17 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 7.7% of the company's total shares outstanding in December 2025, down from 16.1% in September 2025.
• In percentage terms, this reflects as a holdings change of -17.00% quarter on quarter, and a decrease of 29.17% year over year.
• Among the 17 institutional holders of CASI Pharmaceuticals, 4 added to their stakes while 5 trimmed their positions and 8 held steady.
• Collectively, institutional investors decreased their stake in CASI Pharmaceuticals to 1.26Mn shares as of December 2025, a change that is down by 257.57K shares quarter on quarter and down 1.40Mn shares year over year.
• As of December 31, 2025, VR Adviser, LLC held CASI Pharmaceuticals's largest shareholding position with over 987.26K shares, representing 6.08% of total outstanding shares.
• Among the most significant buyers of CASI Pharmaceuticals during December 2025 were CITADEL ADVISORS LLC (14.04K), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (5.21K), UBS Group AG (645), MORGAN STANLEY (2).
• Leading sellers of CASI Pharmaceuticals stock in December 2025 included BANK OF AMERICA CORP /DE/ (234.95K), Woodline Partners LP (32.23K), TWO SIGMA INVESTMENTS, LP (9.48K), RENAISSANCE TECHNOLOGIES LLC (800), SIMPLEX TRADING, LLC (12).
• The top 10 institutional holders of CASI Pharmaceuticals for the quarter ending December 2025 included VR Adviser, LLC (987.26K), Woodline Partners LP (133.41K), RENAISSANCE TECHNOLOGIES LLC (43.10K), TWO SIGMA INVESTMENTS, LP (23.79K), BANK OF AMERICA CORP /DE/ (19.93K), GEODE CAPITAL MANAGEMENT, LLC (18.81K), CITADEL ADVISORS LLC (14.04K), ROYAL BANK OF CANADA (9.95K), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (5.23K), UBS Group AG (659).